Estrella Immunopharma
ESLA
6 hedge funds and large institutions have $166K invested in Estrella Immunopharma in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, reducing their positions, and 1 closing their positions.
16% more capital invested
Capital invested by funds: $143K → $166K (+$22.3K)
0% more ownership
Funds ownership: 0.37% → 0.37% (+0%)
14% less funds holding
Funds holding: 7 → 6 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.54K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.24K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$336 |
ESLA Hedge Fund Activity: Q1 2024 in Review
6 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q1 2024, worth a combined $166K — up 16% from $143K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ESLA and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 3 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $5.54K. The largest seller was UBS Group, exiting entirely with an estimated $336 sold.
- 6 institutional investors held Estrella Immunopharma (ESLA) as of Q1 2024, down from 7 in Q4 2023.
- Funds reported $166K of Estrella Immunopharma stock for Q1 2024, up 16% quarter-over-quarter.
- 0 funds opened new Estrella Immunopharma positions in Q1 2024 and 1 closed out, a net change of -1 holder.
- The largest Estrella Immunopharma buyer in Q1 2024 was Tower Research Capital (TRC), an estimated $5.54K added.
- The largest Estrella Immunopharma seller in Q1 2024 was UBS Group, an estimated $336 sold.
Based on aggregated 13F filings for Q1 2024.